Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 23:14:1102361.
doi: 10.3389/fendo.2023.1102361. eCollection 2023.

The mechanism and therapeutic strategies for neovascular glaucoma secondary to diabetic retinopathy

Yizhen Tang  1   2 , Yan Shi  1   2 , Zhigang Fan  1   2
Affiliations
Review

The mechanism and therapeutic strategies for neovascular glaucoma secondary to diabetic retinopathy

Yizhen Tang et al. Front Endocrinol (Lausanne). .

Abstract

Neovascular glaucoma (NVG) is a devastating secondary glaucoma characterized by the appearance of neovascular over the iris and the proliferation of fibrovascular tissue in the anterior chamber angle. Proliferative diabetic retinopathy (PDR) is one of the leading causes of NVG. Currently increasing diabetes population drive the prevalence rate of NVG into a fast-rising lane. The pathogenesis underlying NVG makes it refractory to routine management for other types of glaucoma in clinical practice. The combination of panretinal photocoagulation (PRP), anti-vascular endothelial growth factor (VEGF) injections, anti-glaucoma drugs, surgical intervention as well as blood glucose control is needed. Early diagnosis and aggressive treatment in time are crucial in halting the neovascularization process and preserving vision. This review provides an overview of NVG secondary to diabetic retinopathy (DR), including the epidemiology, pathogenesis and management, so as to provide a better understanding as well as potential therapeutic strategies for future treatment.

Keywords: diabetic retinopathy; epidemiology; management; neovascular glaucoma; pathogenesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow chart showing the recommended management procedures for NVG secondary to DR. NVG: neovascular glaucoma, IOP: intraocular pressure, VEGF: Vascular endothelial growth factor, PRP: panretinal photocoagulation, PL: perception of light, CP: cyclodestructive procedures.
See this image and copyright information in PMC

References

    1. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res (2007) 26(5):470–85. doi: 10.1016/j.preteyeres.2007.06.001 - DOI - PMC - PubMed
    1. Palma C, Kim D, Singh A, Singh A. Neovascular glaucoma, in glaucoma, Glaucoma Medical Diagnosis and Therapy 2nd ed. Shaarawy TM, Saunders WB, editors (2015), pp. 425–33.
    1. Stamper RL, Lieberman MF, Drake MV. CHAPTER 16 - secondary angle-closure glaucoma, in becker-shaffer's diagnosis and therapy of the glaucomas. Eighth Edition. Stamper RL, Lieberman MF, Drake MV, editors. Edinburgh: Mosby; (2009) p. 212–38.
    1. Narayanaswamy A, Baskaran M, Zheng Y, Lavanya R, Wu R, Wong WL, et al. The prevalence and types of glaucoma in an urban Indian population: the Singapore Indian eye study. Invest Ophthalmol Vis Sci (2013) 54(7):4621–7. doi: 10.1167/iovs.13-11950 - DOI - PubMed
    1. Wong TY, Chong EW, Wong WL, Rosman M, Aung T, Loo JL, et al. Prevalence and causes of low vision and blindness in an urban malay population: the Singapore Malay eye study. Arch Ophthalmol (2008) 126(8):1091–9. doi: 10.1001/archopht.126.8.1091 - DOI - PubMed

Publication types

MeSH terms

Substances